Adaptive Biotechnologies, the leader in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors of the adaptive immune system, and its collaborators from academic institutions around the world will share data further demonstrating the validity and prognostic value of the clonoSEQ® Process for minimal residual disease (MRD) assessment in lymphoid cancers in three oral and eight poster presentations, encompassing six different blood cancer subtypes, at the American Society of Hematology (ASH) Annual Meeting, December 5-8, 2015 in Orland
Adaptive Biotechnologies, the leader in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors (TCRs and BCRs) of the adaptive immune system, today published a study detailing a powerful new tool that enables sensitive and quantitative monitoring of T cells specific for hundreds, and possibly thousands, of antigens simultaneously and in a single experiment.
Goldman Sachs (NYSE:GS) is recognizing Adaptive Biotechnologies’ Chad Robins, President, Chief Executive Officer and Co-Founder, and Harlan Robins, Chief Scientific Officer and Co-Founder, as part of the 100 Most Intriguing Entrepreneurs of 2015 at its Builders + Innovators Summit in Santa Barbara, California.
Adaptive Biotechnologies and collaborators at Brigham and Women’s Hospital today announced publication of a study demonstrating that the company’s revolutionary immunosequencing platform, which utilizes next-generation sequencing and advanced bioinformatics to sensitively profile all of the T cells in a biological sample, adds value in delivering more definitive diagnoses of cutaneous T-cell lymphoma (CTCL).
Adaptive Biotechnologies, the leader in profiling T- and B-cell receptors of the adaptive immune system, and Nature Immunology, Nature Medicine, Nature Biotechnology and Nature Genetics are proud to be presenting A Nature Conference: Immune Profiling in Health and Disease, September 9-11, 2015 in Seattle, Washington. This inaugural conference brings together leading experts from around the world to discuss the clinical and research applications that can arise from immunosequencing and other high-dimensional technologies. The unique program with editorial content provided by the Nature Publishing Group along with a world-class speaker’s list has attracted over 200 scientists from 20 different countries. Keynote presentations will be given by Mark Davis from Stanford University and James Allison from MD Anderson Cancer Center.
Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, announces a publication in Science Translational Medicine on a novel first-in-class technology for pairing T-cell receptor (TCR) alpha and beta chain sequences at high throughput. The pairSEQ™ Assay employs a pioneering proprietary process that combines Adaptive’s foundational immunoSEQ® Platform for sequencing each TCR chain independently with a sophisticated bioinformatics framework to facilitate pairing of these chains. The pairSEQ Assay enables highly accurate, rapid and scalable pairing of up to hundreds of thousands of TCR alpha or beta sequences in a single experiment and can be applied to the process of therapeutic discovery, including the identification of highly promising TCRs for adoptive T-cell therapy.
Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, announced today the appointment of Chad Cohen as its new Chief Financial Officer, effective immediately. Mr. Cohen has served on Adaptive’s Board of Directors since March 2015. Most recently, Mr. Cohen served as CFO for Zillow Group, where he oversaw all finance, treasury and accounting functions and led the finance organization through Zillow's 2011 IPO and nine acquisitions.
Adaptive Biotechnologies today announced the recent publication of a study in JAMA Oncology that demonstrates that measurement of minimal residual disease (MRD) is a critical tool in evaluating response to new highly effective drug combinations for the treatment of multiple myeloma.
Adaptive Biotechnologies, the leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors, will present data from a study of more than 400 children with acute lymphoblastic leukemia (ALL), some observed for more than a decade, demonstrating that the company’s immunosequencing platform, available clinically in the United States as the clonoSEQ® Process, can more sensitively detect minimal residual disease (MRD) than flow cytometry, and that MRD detected using this method is predictive of a patient’s ultimate outcome. These data and more will be presented at the 20th Congress of the European Hematology Association in Vienna, Austria, June 11-14, 2015.
Adaptive Biotechnologies announced the publication of a joint study with the Children’s Oncology Group (COG) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) demonstrating that minimal residual disease detected using next-generation sequencing (NGS), available clinically as the clonoSEQ® MRD Test through the company’s CLIA-certified laboratory, can more accurately predict relapse and survival compared to multichannel (6-color) flow cytometry in pediatric acute lymphoblastic leukemia (ALL) patients undergoing donor stem cell transplants.
Visit us at the Association for Molecular Pathology Annual Meeting in Austin, TX to learn about our new products, demo the immunoSEQ Analyzer, and speak with our immunosequencing experts and scientific advisors.
Visit us at the Society for Immunotherapy of Cancer Annual Meeting in Boston, MA to learn about our new products, demo the immunoSEQ Analyzer, and speak with our immunosequencing experts and scientific advisors.